Gilead Sciences was founded by Michael Riordan in 1987 with a $2 million investment from Menlo Ventures.
The company focused on making small strands of DNA to assess the potential of gene therapy. Gilead Sciences developed small molecule antiviral therapeutics in 1991, one of which was tenofivir, which became one of the most widely-used anti AIDS drugs.
Donald Rumsfield became a board member at Gilead Sciences in 1988, and was the chairman in 2001 when he was stepped down to become the U.S. Secretary of Defense. At the time he owned between $5 million and $25 million of Gilead stock.
Today Gilead Sciences is a biotech company with treatments for hepatitis, HIV, infections related to AIDS, cardiovascular drugs, and respiratory and ophthalmic medicines.
Gilead Sciences is traded publicly on the NASDAQ under the ticker symbol GILD, is a member of the S&P 500, is #324 in the Fortune 500, has 6,100 employees, and had $17.44 billion in revenue in 2013.
Gilead Sciences
Gilead Sciences was founded by Michael Riordan in 1987 with a $2 million investment from Menlo Ventures.
The company focused on making small strands of DNA to assess the potential of gene therapy. Gilead Sciences developed small molecule antiviral therapeutics in 1991, one of which was tenofivir, which became one of the most widely-used anti AIDS drugs.
Donald Rumsfield became a board member at Gilead Sciences in 1988, and was the chairman in 2001 when he was stepped down to become the U.S. Secretary of Defense. At the time he owned between $5 million and $25 million of Gilead stock.
History
Today Gilead Sciences is a biotech company with treatments for hepatitis, HIV, infections related to AIDS, cardiovascular drugs, and respiratory and ophthalmic medicines.
Gilead Sciences is traded publicly on the NASDAQ under the ticker symbol GILD, is a member of the S&P 500, is #324 in the Fortune 500, has 6,100 employees, and had $17.44 billion in revenue in 2013.